Evidence map›Paper›PMID 39534344›Full record

ArticleJTCVS open2024

Lymphatic vascular invasion: Diagnostic variability and overall survival impact on patients undergoing surgical resection.

John Varlotto, Rick Voland, Negar Rassaei, Dani Zander, Malcolm M DeCamp, Jai Khatri, Yousef Shweihat, Kemnasom Nwanwene, Maria Tria Tirona, Thomas Wright and 4 more

Abstract read
In one paragraph

Article in JTCVS open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

John VarlottoDepartment of Oncology, Edwards Comprehensive Cancer Center/Marshall University, Huntington, WVa.
Rick VolandDepartment of Ophthalmology, University of Wisconsin, Madison, Wis.
Negar RassaeiCenters for Disease Control and Prevention, Atlanta, Ga.
Dani ZanderDepartment of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio.
Malcolm M DeCampDivision of Cardiothoracic Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wis.
Jai KhatriDepartment of Oncology, Edwards Comprehensive Cancer Center/Marshall University, Huntington, WVa.
Yousef ShweihatDepartment of Internal Medicine, Marshall Health, Huntington, WVa.
Kemnasom NwanweneDepartment of Oncology, Edwards Comprehensive Cancer Center/Marshall University, Huntington, WVa.
Maria Tria TironaDepartment of Oncology, Edwards Comprehensive Cancer Center/Marshall University, Huntington, WVa.
Thomas WrightDepartment of Internal Medicine, Marshall Health, Huntington, WVa.
Toni PaciolesDepartment of Oncology, Edwards Comprehensive Cancer Center/Marshall University, Huntington, WVa.
Muhammad JamilDepartment of Oncology, Edwards Comprehensive Cancer Center/Marshall University, Huntington, WVa.
Khuram AnwarDepartment of Oncology, Edwards Comprehensive Cancer Center/Marshall University, Huntington, WVa.
John FlickingerDepartment of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The diagnostic criteria of lymphatic vascular invasion have not been standardized. Our investigation assesses the factors associated with lymphatic vascular invasion positive tumors and the impact of lymphatic vascular invasion on overall survival for patients with non-small cell lung cancer undergoing (bi)lobectomy with an adequate node dissection. Methods: The National Cancer Database was queried from the years 2010 to 2015 to find surgical patients who underwent lobectomy with at least 10 lymph nodes examined (adequate node dissection) and with known lymphatic vascular invasion status. Paired Results: Lymphatic vascular invasion status was reported in 91.6% and positive in 23.4% of 28,842 eligible patients. Academic medical centers, institutions with populations more than 1,000,000, and the mid-Atlantic region reported higher rates of lymphatic vascular invasion positive tumors as well as overall survival compared with other cancer centers. Lymphatic vascular invasion was independently associated with a significant decrement in overall survival as per multivariable analysis and propensity score matching. Propensity score matching demonstrated that lymphatic vascular invasion was associated with a significant decrement in overall survival for all histologies, tumor grades, tumor sizes, and stages, except for more advanced pathologic stages T3/III/N2 and larger tumors greater than 4 cm for which overall survival was trending worse with lymphatic vascular invasion positive. Conclusions: Lymphatic vascular invasion positive varies based on hospital location/type and population, but it was associated with a decrement in overall survival that was independent of pathologic T/N/overall stage, histology, and tumor grade. Lymphatic vascular invasion must be standardized and considered as a staging variable and should be considered as a sole determinant for prognosis, especially for those with earlier-stage and smaller tumors.

Indexed as

diagnostic variancelung cancer surgerylymphatic vascular invasionprognosis

Identifiers

PMID39534344
PMCPMC11551250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.